Company Overview and News

0
BOURBON : Evolution au sein de la Direction générale

2018-07-11 globenewswire
BOURBON Corporation annonce la démission d'Astrid de Bréon de son mandat social de Directrice Générale Déléguée en charge des finances et de l'administration à compter de ce jour. Depuis son arrivée le 1er Février 2017, Astrid de Bréon a largement contribué à la transformation de BOURBON et à la mise en oeuvre du réaménagement durable de l'endettement financier de l'entreprise. Elle continuera d'exercer ses fonctions de Directrice Générale Adjointe en charge des finances et de l'administration jusqu'à son prochain remplacement à ce poste et son départ de l'entreprise.
GBB

0
BOURBON: Evolution within the general management

2018-07-11 globenewswire
BOURBON Corporation announces the resignation of Astrid de Bréon from her position as Chief Financial Officer effective today. Since her arrival on February 1st, 2017, Astrid de Bréon has largely contributed to BOURBON's transformation and to the sustainable reorganization of the company's financial debt. She will continue to exercice her duties untill her replacement and departure from the company.
GBB

0
BOURBON : Bilan semestriel du contrat de liquidité contracté avec CM CIC Market Solutions

2018-07-04 globenewswire
Au titre du contrat de liquidité confié par la société BOURBON CORPORATION à CM-CIC Market Solutions, à la date du 30 juin 2018 les moyens suivants figuraient au compte de liquidité :
GBB

0
BOURBON: Half-year liquidity contract statement contracted with CM CIC Market Solutions

2018-07-04 globenewswire
Under the liquidity contract signed between BOURBON CORPORATION and CM CIC Market Solutions, the following amounts were shown in the liquidity account on June 30, 2018:
GBB

0
BOURBON : Principales décisions de l'Assemblée Générale Mixte du 30 mai 2018

2018-05-31 globenewswire
L'Assemblée Générale Mixte des actionnaires de BOURBON Corporation SA s'est tenue le 30 mai 2018 à 15 heures au Palais Brongniart - Place de la Bourse - à Paris (75002), sous la présidence de M. Jacques de Chateauvieux.
GBB

0
BOURBON: Main decisions of the Combined General Meeting of May 30, 2018

2018-05-31 globenewswire
The Combined General Shareholders' Meeting of BOURBON Corporation SA was held on May 30, 2018 at 3 pm in Palais Brongniart - Place de la Bourse - Paris, and chaired by Mr. Jacques de Chateauvieux.
GBB

0
BOURBON : Information financière du 1er trimestre 2018

2018-05-03 globenewswire
Le chiffre d'affaires ajusté du 1er trimestre 2018 s'élève à 171 millions d'euros (chiffre d'affaires consolidé de 157,6 millions d'euros), en retrait de 13,2 % par rapport au 4ème trimestre 2017, impacté par la baisse de l'activité dans les services Subsea
GBB

0
BOURBON: 1st Quarter 2018 Financial information

2018-05-03 globenewswire
Adjusted revenue for the 1st quarter 2018 amounted to €171 million (consolidated revenue was €157.6 million), down 13.2% compared to the 4th quarter 2017, impacted by the reduced activity in Subsea Services
GBB

0
BOURBON primé "Shipowner of the Year" pour son programme "Smart Shipping" par GST & Shipping2030

2018-04-27 globenewswire
BOURBON a reçu le prix « Shipowner of the Year » à l'occasion de la conférence GST & Shipping2030 à Copenhague. Ce prix récompense le programme « Smart Shipping » déployé par le groupe et constitue un pilier essentiel du plan d'action stratégique #BOURBONINMOTION visant à accélérer sa transformation et à s'adapter aux nouvelles exigences des clients pétroliers.
GBB BVVBY BVINV BVI

0
BOURBON wins the "Shipowner of the Year" award by GST & Shipping2030 for its "Smart Shipping" program

2018-04-27 globenewswire
BOURBON has been awarded the "Shipowner of the Year" award in the context of the GST & Shipping 2030 conference, which was held at the end of March 2018 in Copenhagen. This award recognizes the "Smart Shipping" program that is being deployed by the group and represents an essential pillar of the #BOURBONINMOTION strategic action plan aimed at accelerating its transformation and adapting to oil & gas clients' new requirements.
GBB BVVBY BVINV BVI

0
BOURBON : Communiqué de mise à disposition Document de Référence / Rapport financier annuel 2017

2018-04-25 globenewswire
Le Document de Référence 2017 a été déposé auprès de l'Autorité des Marchés Financiers (AMF) sous le numéro D.18-0384 en date du 25 avril 2018.
GBB

0
BOURBON : Convocation de l'Assemblée Générale des porteurs de TSSDI de BOURBON Corporation

2018-04-05 globenewswire
Les porteurs d'obligations perpétuelles subordonnées de dernier rang (TSSDI) à taux fixe à variable (Undated Deeply Subordinated Fixed to Floating Rate Bonds) émises par la société au titre d'une émission initiale d'un montant total en principal de 100 millions d'euros le 24 octobre 2014 et d'une seconde émission d'obligations assimilées et formant une souche unique avec les obligations initiales, d'un montant total en principal de 20 millions d'euros le 24 avril 2015, sont convoqués en assemblée générale le 20 avril 2018 à 14h30 à l'EMD, Montée de l'Université, rue Joseph Biaggi à Marseille (France).
GBB

0
BOURBON: Convening to the general meeting of the holders of BOURBON Corporation's Bonds

2018-04-05 globenewswire
The holders of Undated Deeply Subordinated Fixed to Floating Rate Bonds (the "Bonds" and the "Bondholders") issued by the company under an initial issuance for a total principal amount of €100 million on October 24, 2014 and a second issuance of assimilated bonds and forming a single series with the initial bonds, for a total principal amount of €20 million on April 24, 2015, are convened to the general meeting of Bondholders on April 20, 2018, at 2:30 p.
GBB

0
Geopolitical Risk Remains In The Background

2018-03-30 seekingalpha
A Eurogroup meeting on March 12 has been the key moment for the Brexit negotiations. At this meeting, the Europeans set the guidelines for their transition period discussions with the UK, aiming for a fully crafted withdrawal agreement by October or November.
GBB HOG

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...